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severe reﬂux oesophagitis (RO), Los Angeles grades C or D
compared with standard adult doses of other proton pump
inhibitors (PPIs), i.e., generic lansoprazole 30 mg od, generic
omeprazole 20 mg od, pantoprazole 40 mg od, and rabeprazole
20 mg od. METHODS: A simple decision-tree model was
designed to evaluate the cost-effectiveness of esomeprazole over a
6-month time horizon from the perspective of the UK National
Health Service. Healing rate probabilities were extrapolated
from the results of a meta-analysis of 6 randomised, controlled
trials that compared esomeprazole with other PPIs in adults who
had endoscopically-conﬁrmed RO. Data from the IMS Disease
Analyser was used to estimate the average duration of a course of
PPI therapy prescribed to adolescents in the UK. Health state
valuations were estimated from a European study that used Time
Trade Off to obtain utilities scores from a sample of more than
1,000 patients with GORD symptoms. RESULTS: Esomeprazole
was a cost-effective treatment option for adolescents with
moderate or severe RO versus all other standard-dose PPIs.
For example, incremental cost-effectiveness ratios ranged from
£2,200/QALY (95% CI, £1,100/QALY to £5,600/QALY) and
£15,200/QALY (95% CI, £6,700 to >£80,000/QALY), when
esomeprazole was compared with pantoprazole (in adolescents
with severe RO) and generic lansoprazole (in adolescents with
moderate RO), respectively. The probability of esomeprazole
being cost-effective at a threshold of £30,000/QALY was greater
than 84% for all the analyses that were undertaken. CONCLU-
SION: Esomeprazole is a cost-effective treatment for adolescent
patients who are presumed to have moderate or severe reﬂux
oesophagitis.
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OBJECTIVES: Determine which new generation proton pump
inhibitor (PPI) is most cost-effective in the treatment of GERD
after omeprazole failure as well as their expected impact on
Spanish NHS budget. METHODS: A pharmacoeconomic deter-
ministic model was developed, based on data extracted from
literature, form an NHS perspective to compare esomeprazole
(ESO40 mg/d), lansoprazole (LANSO30 mg/d), pantoprazole
(PANTO40 mg/d) and rabeprazole (RABE20 mg/d) in patients
with GERD refractory to omeprazole (patients without remission
or remaining symptomatic after OME 20 mg/day 4 weeks). The
effectiveness measure was symptom free-days after 12 months
of treatment. The costs included were drugs and health care
utilization resources (diagnostic methods, physicians visits and
surgery), expressed as 2006 €. Moreover a budget impact model
was done to know the affordability of most cost-effective drug
utilization in a 1000 patients cohort. RESULTS: ESO provide
higher remission rates (238 days without symptoms) than the
other alternatives: LANSO-213 days; PANTO-203 days; RABE-
205 days. The annual cost by patient are: 652€-ESO, 703€-
LANSO, 734€-PANTO; 706€-RABE. The analysis indicates that
ESO being a dominant therapy in this case. The expected cost by
patient is 428.84€ (310 symptoms free-days), based on 2006
treatment patterns. Increasing the ESO utilization on 25, 50, 75
& 100%, instead of less effective and costly drugs, could produce
potential savings for the Spanish NHS: 720€, 1430€, 2000€ &
2860€, respectively; which would allow for the treatment of
more patients with the same budget: 1.68, 3.35, 4.69 and 6.71
additional patients, correspondingly. CONCLUSION: ESO is the
most cost-effective and efﬁcient PPI in the treatment of GERD
after omeprazole failure in Spain.
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AND COSTS IN PATIENTS ON OPIOIDTHERAPY
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OBJECTIVES: To assess the impact of constipation on opioid use
patterns, resource utilization, and costs in patients on opioid
therapy. METHODS: A retrospective study was conducted in
patients who initiated opioid therapy between 1/1/99 and 12/31/
05. Patients were identiﬁed from longitudinal insurance claims
from US health plans. An index date was deﬁned as the date of
the 1st pharmacy claim for an opioid. Patients had 30 days of
opioid use and continuous plan coverage for 6 months before
and 12 months after their index date. Outcomes were assessed
over 12 months following the index date. Constipation was
deﬁned as evidence of 1 ICD-9 code of 564.0 in the follow-up
period. Opioid use patterns were compared between patients
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with constipation and 1:1 matched controls without constipa-
tion. Two- part semi-logarithmic multivariate regression models
were estimated to assess the impact of constipation on all-cause
resource utilization and costs. Smearing estimates were applied
to interpret results of the semi-logarithmic models. RESULTS:
We identiﬁed 39,485 patients of whom 2,519 (6.4%) had con-
stipation. Most patients with constipation were female (66%)
and 45 years old (68%). Compared to controls, the constipa-
tion group had higher rates of concurrent use of 2 opioids
(36% vs 24%; p < 0.001), discontinuation (31% vs 25%;
p < 0.001), and switching (45% vs 28%; p < 0.001) between
opioids. Patients with constipation were more likely to have
inpatient admission (odds ratio [OR] = 2.13; p < 0.001), emer-
gency (OR = 2.25; p < 0.001), outpatient visits (OR = 9.45;
p < 0.001), skilled nursing (OR = 2.26; p < 0.001), hospice
(OR = 2.27; p < 0.001) and home health services (OR = 1.54;
p < 0.001). Patients with constipation had signiﬁcantly higher
all-cause costs for emergency ($1,277 vs. $588), outpatient
($3,635 vs $1,861), nursing facility ($1,885 vs. $613), home
health ($1,909 vs. $1,069) and prescription drug ($12,005 vs
$6,809) services compared to patients without constipation.
CONCLUSION: Presence of constipation in opioid-treated
patients was found to have signiﬁcant impact on opioid use
patterns, health care utilization, and associated costs.
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OBJECTIVES: To estimate the economic burden of Digital
Ulcers (DU) in patients affected by Systemic Sclerosis (SSc, scle-
roderma), in the perspective of the NHS, patients, and society.
METHODS: Pilot, observational study based on a retrospective,
one-year, data collection of clinical characteristics and consump-
tion of resources in the target population, at the Rheumatology
Unit of the University Hospital in Padova. EC approval and
informed consent were obtained. Clinical records of adults with
limited/diffuse SSc, who developed >1 new DU (from September
2005 to April 2006) were analysed. Direct cost and indirect cost
per patient/year were calculated using 2007 published tariffs and
market values. RESULTS: Twenty patients (90% females) (age
51 +/- 12 yr), 60% affected by limited SSc and 80% by severe
DU (average nDU = 3) were included. Twenty percent of patients
had longer SSc history and more severe DU. All patients received
home treatments; 55% also received outpatient care; 85%
received on average 3.7 cycles of prostanoids (iloprost or alpros-
tadil) in the DH setting, 15% were also hospitalised. DU com-
plications, mostly superinfections, occurred in 85% of patients.
80% of patients healed. In the NHS perspective, cost of DU is on
average €23,730 per patient/year, 71.8% due to DH treatments
(including prostanoids) and 23.7% to management of complica-
tions; cost per patient varies from €20,533 (no complications,
average nDU = 1) to €24,295 (with complications, average
nDU = 4); main cost driver is the number of DH accesses. Out-
of-pocket expenditure is lower for patients with complications
(€360 vs. €900/year) as cost of complications is mainly borne by
the NHS. Cost/patient/year is on average €26,756 in the societal
perspective (€27,309 and €23,619 with/without complications);
indirect costs increase when complications occur. CONCLU-
SION: Despite the small sample, DU economic burden is relevant
because of DH treatments and complications’ management. In
absence of complications, cost of management shifts to patients’
charge.
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OBJECTIVES: Crohn’s disease (CD) is a potentially expensive
disease as it is a chronic, not curable condition with high hospi-
talisation rates. The objective of the study was to estimate the
health care resource use and epidemiology in a large UK popu-
lation. METHODS: This was a retrospective study using NHS
inpatient data (HES data) from 2001 over a period of 5 years
representing England (population in 2001 49,140,000). To
compare these results data from the region of Cardiff, Wales, UK
(population in 2003 approximately 434,000) was used. This data
contains inpatient, outpatient, biochemistry and mortality data
over a period of at least 12 years that has undergone record
linkage. Patients included were those with a diagnosis of CD
(ICD-10 K50*) as cause of admission. Number, type and method
of admission, incidence and survival were analysed. HRGs were
used to calculate inpatient costs. RESULTS: A total of 18,573
patients were identiﬁed in the NHS data [644 Cardiff data], of
whom 7,666 (41.3%) [250 (38.8%) Cardiff data] were male. The
average incidence was 14 per 100,000 per year. Mean length of
stay for primary index admissions was 9.2 (SD 14.7) days and
mean costs 2304 (SD 2778). Re-admission rates (primary or
secondary ICD code) in the year after index admission were 1.36
(SD 3.26) and disease related 0.83 (SD 2.34) per patient; average
length of stay per admission were 6.5 (SD 14.6), average costs
1776 (SD 2692). Surgery rate in the year after index admis-
sion was 0.16 (SD 0.46); average length of stay 12.5 (SD 22.1),
average costs per surgery 4048 (SD 4158). The rates declined
over the follow-up years. Hospital days, costs and rates approxi-
mately matched the Cardiff data, but were slightly higher. CON-
CLUSION: This study provides epidemiological and resource use
information on patients with CD. It conﬁrms the high resource
use and gives insight into determinants.
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OBJECTIVES: Ulcerative colitis (UC) is a potentially expensive
disease since it is a chronic condition with high hospitalisation
rates. The objective of the study was to estimate the health
care resource use and epidemiology in a large UK population.
METHODS: This was a retrospective study using NHS inpatient
data (HES data) from 2001 over a period of 5 years representing
England (population in 2001 49,140,000). To compare these
results data from the region of Cardiff, Wales, UK (population in
2003 approximately 434,000) was used. This data contains inpa-
tient, outpatient, biochemistry and mortality data over a period
of at least 12 years that has undergone record linkage. Patients
included were those with a diagnosis of UC (ICD-10 K51*) as
cause of admission. Number, type and method of admission,
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